We are using cookies to give you the best experience on our site. Cookies are files stored in your browser and are used by most websites to help personalise your web experience.

By continuing to use our website without changing the settings, you are agreeing to our use of cookies.

Find out more
You are here:
> > > > Can adalimumab affect fertility, pregnancy or breastfeeding?

Can adalimumab affect fertility, pregnancy or breastfeeding?

If you're planning to try for a baby, if you become pregnant, or if you're thinking of breastfeeding we suggest you discuss your medications with your rheumatologist.

Current guidelines state that adalimumab can be used during pregnancy and in men trying to father a child.

If it's used during pregnancy it will usually be stopped after six months. If it's used after this, then it's possible (but not proven) that it may increase the risk of infection in the newborn baby. However, if there's concern that your arthritis may flare up if adalimumab is stopped then you can continue with it throughout pregnancy. In this case, your baby shouldn't have any live vaccines until they're seven months old.

Women who are also on methotrexate should stop this drug at least three months before trying for a baby. The guidelines state there's no need for men to stop methotrexate when trying to father a baby.

There's only limited information about the use of adalimumab by women who are breastfeeding. Small amounts of the drug may pass into the breast milk, but this doesn't appear to be harmful. If you were also taking methotrexate before your pregnancy you should not re-start this until you've stopped breastfeeding.


0800 5200 520

Our new helpline: Call us for free information, help and advice on your type of arthritis.

All calls are recorded for training and quality purposes

More Information Close
For more information, go to
Arthritis Research UK fund research into the cause, treatment and cure of arthritis. You can support Arthritis Research UK by volunteering, donating or visiting our shops.